Hopkins and BMS announce five-year collaboration to study resistance to checkpoint blockers and develop combination immunotherapies.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE JOHNS HOPKINS UNIVERSITY and Bristol-Myers Squibb Co. announced a five-year collaboration aimed to answer why some patients respond to checkpoint blockers and some do not, and to develop more effective combination immunotherapies. Projects included in the collaboration will span laboratory research on patients’ tumor samples and several early-stage clinical trials led by Johns Hopkins...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login